Ribociclib-induced liver injury: a case report
BackgroundIdiosyncratic drug-induced liver injury (DILI) is a rare, unpredictable hepatic adverse event and the most common cause of acute liver failure in Europe and the US. Ribociclib is a potent Cyclin-dependent kinase 4 and 6 (CDK4/6)-inhibitor administered for advanced hormone-receptor (HR)-pos...
Main Authors: | Sofia Schaeffer, Christian Lutz, Michael Dobbie, Luigi M. Terracciano, Matthias Matter, Jürg Vosbeck, Markus H. Heim, Christine Bernsmeier |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-12-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1256783/full |
Similar Items
-
Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial (AMICA)
by: Thomas Decker, et al.
Published: (2023-12-01) -
The effect of low HER2 expression on treatment outcomes in metastatic hormone receptor positive breast cancer patients treated with a combination of a CDK4/6 inhibitor and endocrine therapy: A multicentric retrospective study
by: Eda Caliskan Yildirim, et al.
Published: (2023-08-01) -
Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b CompLEEment-1 trial
by: Borstnar Simona, et al.
Published: (2022-05-01) -
Ribociclib in patient with hormone-positive HER2-negative breast cancer with brain metastases: a case report
by: N. S. Prizova, et al.
Published: (2022-06-01) -
Ribociclib in newly diagnosed hepatitis B infection: A case report
by: Fabrizio Di Costanzo, et al.
Published: (2023-06-01)